世界最新医学信息文摘（电子版）
世界最新醫學信息文摘（電子版）
세계최신의학신식문적（전자판）
World Latest Medicine Information
2013年
5期
7-8,11
,共3页
宫颈癌%癌抗原125%糖链抗原19-9%临床特征
宮頸癌%癌抗原125%糖鏈抗原19-9%臨床特徵
궁경암%암항원125%당련항원19-9%림상특정
Cervical cancer%CA125%CA19-9%Clinical features
目的探讨宫颈癌患者血清癌抗原125（CA125）和糖链抗原19-9（CA19-9）的检测及其意义。方法144例宫颈癌患者确诊后次日清晨空腹采外周血，用化学化光法检测血清CA125和CA19-9水平，并与90例健康体检者对照比较。结果宫颈癌患者血清中CA125和CA19-9阳性率明显高于健康体检者P ＜0.01(u=2.687,3.150)；CA125和CA19-9阳性率与有淋巴结转移和病理分级及临床分期的增高而呈正相关；联合检测CA125和CA19-9能提高宫颈癌特异度，减少误诊率。结论联合检测血清中CA125和CA19-9水平对宫颈癌判断、临床分期和疾病治疗后的动态监测-预测是否复发等方面具有一定的参考价值。
目的探討宮頸癌患者血清癌抗原125（CA125）和糖鏈抗原19-9（CA19-9）的檢測及其意義。方法144例宮頸癌患者確診後次日清晨空腹採外週血，用化學化光法檢測血清CA125和CA19-9水平，併與90例健康體檢者對照比較。結果宮頸癌患者血清中CA125和CA19-9暘性率明顯高于健康體檢者P ＜0.01(u=2.687,3.150)；CA125和CA19-9暘性率與有淋巴結轉移和病理分級及臨床分期的增高而呈正相關；聯閤檢測CA125和CA19-9能提高宮頸癌特異度，減少誤診率。結論聯閤檢測血清中CA125和CA19-9水平對宮頸癌判斷、臨床分期和疾病治療後的動態鑑測-預測是否複髮等方麵具有一定的參攷價值。
목적탐토궁경암환자혈청암항원125（CA125）화당련항원19-9（CA19-9）적검측급기의의。방법144례궁경암환자학진후차일청신공복채외주혈，용화학화광법검측혈청CA125화CA19-9수평，병여90례건강체검자대조비교。결과궁경암환자혈청중CA125화CA19-9양성솔명현고우건강체검자P ＜0.01(u=2.687,3.150)；CA125화CA19-9양성솔여유림파결전이화병리분급급림상분기적증고이정정상관；연합검측CA125화CA19-9능제고궁경암특이도，감소오진솔。결론연합검측혈청중CA125화CA19-9수평대궁경암판단、림상분기화질병치료후적동태감측-예측시부복발등방면구유일정적삼고개치。
Objective To investigate the Inspection and significance of cervical cancer patients with serum cancer antigen 125 (CA125) and carbohydrate antigen 19-9 (CA19-9). Methods:144 cases of cervical cancer are diagnosed early the next morning fasting collected peripheral blood, the use the chemical of light law of Serum CA125 and CA19-9 level, compared with 90 cases of healthy control.Results:Positive rate of CA125 and CA19-9 in the serum of patients with cervical cancer was significantly higher than the healthy subjects P <0.01 (u=2.687,3.150);positive rate of CA125 and CA19-9 with lymph node metastasis and pathological grading and clinical staging increased and was positively correlated;combined detection of CA125 and CA19-9 can improve the specificity of cervical cancer, reduce the rate of misdiagnosis. Conclusion:Combined detection of serum CA125 and CA19-9 level has established reference value for cervical cancer judgment, clinical stage and disease progression.
